Linked Data API

Show Search Form

Search Results

1133166
star this property registered interest false more like this
star this property date less than 2019-06-19more like thismore than 2019-06-19
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether patients whose prescription for a cannabis-based medical product is blocked by an NHS trust can appeal that decision. more like this
star this property tabling member constituency Gower remove filter
star this property tabling member printed
Tonia Antoniazzi more like this
star this property uin 266861 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-06-27more like thismore than 2019-06-27
star this property answer text <p>In line with routine clinical practice patients wishing to seek a second opinion will be supported to do so. In the first instance clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then National Health Service trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support NHS trusts in identifying a suitable NHS specialist for a second opinion. Processes may differ in Scotland, Wales and Northern Ireland.</p> more like this
star this property answering member constituency South Ribble remove filter
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-27T12:42:09.417Zmore like thismore than 2019-06-27T12:42:09.417Z
unstar this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4623
unstar this property label Biography information for Tonia Antoniazzi more like this
1133167
star this property registered interest false more like this
star this property date less than 2019-06-19more like thismore than 2019-06-19
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with (a) NHS England, (b) drug manufacturers and (c) the National Institute for Health and Care Excellence on funding for licensed cannabis-based products. more like this
star this property tabling member constituency Gower remove filter
star this property tabling member printed
Tonia Antoniazzi more like this
star this property uin 266862 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-06-27more like thismore than 2019-06-27
star this property answer text <p>The Department is in regular contact with the National Institute for Health and Care Excellence (NICE) and NHS England colleagues about a range of issues and has not met with drug manufacturers on funding of licensed cannabis-based products.</p><p>Sativex is currently the only licensed cannabis-based product available in the United Kingdom. NICE considered the clinical and cost effectiveness of Sativex in the development of its clinical guideline on the management of multiple sclerosis published in 2014. NICE was not able to recommend Sativex as a cost-effective use of NHS resources for the treatment of spasticity in people with multiple sclerosis. Sativex is not therefore routinely funded by the NHS in England for use in the treatment of multiple sclerosis, although clinicians are able to make a request for exceptional funding for individual patients who they think may benefit from treatment.</p><p>NICE has been asked to develop clinical guidelines on cannabis-based products for medicinal use and is expected to look at the clinical and cost effectiveness of treatments, including Sativex, as part of this work. This is expected to be published by October 2019.</p>
star this property answering member constituency South Ribble remove filter
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-27T12:43:17.543Zmore like thismore than 2019-06-27T12:43:17.543Z
unstar this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4623
unstar this property label Biography information for Tonia Antoniazzi more like this